JP5938876B2 - Ｃｄ６９アンタゴニストを含む肝炎治療用組成物 - Google Patents

Ｃｄ６９アンタゴニストを含む肝炎治療用組成物 Download PDF

Info

Publication number
JP5938876B2
JP5938876B2 JP2011247036A JP2011247036A JP5938876B2 JP 5938876 B2 JP5938876 B2 JP 5938876B2 JP 2011247036 A JP2011247036 A JP 2011247036A JP 2011247036 A JP2011247036 A JP 2011247036A JP 5938876 B2 JP5938876 B2 JP 5938876B2
Authority
JP
Japan
Prior art keywords
hepatitis
antibody
antagonist
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011247036A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012102100A (ja
JP2012102100A5 (enExample
Inventor
俊憲 中山
俊憲 中山
明洋 長谷川
明洋 長谷川
白井　睦訓
睦訓 白井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiba University
Yamaguchi University
Original Assignee
Chiba University
Yamaguchi University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiba University, Yamaguchi University filed Critical Chiba University
Publication of JP2012102100A publication Critical patent/JP2012102100A/ja
Publication of JP2012102100A5 publication Critical patent/JP2012102100A5/ja
Application granted granted Critical
Publication of JP5938876B2 publication Critical patent/JP5938876B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011247036A 2010-11-12 2011-11-11 Ｃｄ６９アンタゴニストを含む肝炎治療用組成物 Active JP5938876B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/945,153 2010-11-12
US12/945,153 US8440195B2 (en) 2010-11-12 2010-11-12 Inhibition of CD69 for treatment of inflammatory conditions

Publications (3)

Publication Number Publication Date
JP2012102100A JP2012102100A (ja) 2012-05-31
JP2012102100A5 JP2012102100A5 (enExample) 2015-01-22
JP5938876B2 true JP5938876B2 (ja) 2016-06-22

Family

ID=46047944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011247036A Active JP5938876B2 (ja) 2010-11-12 2011-11-11 Ｃｄ６９アンタゴニストを含む肝炎治療用組成物

Country Status (2)

Country Link
US (2) US8440195B2 (enExample)
JP (1) JP5938876B2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440195B2 (en) 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
US11655298B2 (en) * 2016-10-21 2023-05-23 Yamaguchi University Composition for treating fulminant acute pneumonia including CD69 antagonist
JP6944701B2 (ja) * 2016-10-21 2021-10-06 国立大学法人山口大学 ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物
WO2024112867A1 (en) 2022-11-23 2024-05-30 University Of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
RS51737B (sr) * 2000-02-21 2011-10-31 Laboratoires Serono Sa. Korišćenje inhibitora il-18
EP2347767A3 (en) * 2003-01-31 2013-06-12 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
WO2004103403A1 (ja) * 2003-05-23 2004-12-02 Immuno-Biological Laboratories Co., Ltd. 免疫担当細胞活性化阻害剤およびその用途
AU2004244626A1 (en) * 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
JP2007022993A (ja) * 2005-07-20 2007-02-01 Chiba Univ アレルギー性喘息の治療薬
US8440195B2 (en) 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions

Also Published As

Publication number Publication date
US20130224111A1 (en) 2013-08-29
US10449252B2 (en) 2019-10-22
JP2012102100A (ja) 2012-05-31
US8440195B2 (en) 2013-05-14
US20120121503A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
US12378310B2 (en) Antibodies specific to folate receptor alpha
US20210221907A1 (en) Antibodies specific to trophoblast antigen 2 (trop2)
CN104245731B (zh) 抗乙型流感病毒的广泛保护性人单克隆抗体及其使用方法
AU2005339476B2 (en) Neutralizing antibodies and methods of use thereof
JP2022174167A (ja) Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
EP2956171B1 (en) Methods to protect against and treat multiple sclerosis
BR112020015736A2 (pt) Anticorpo anti-b7-h4, fragmento de ligação a antígeno do mesmo e uso farmacêutico do mesmo
US12364770B2 (en) Antibodies specific to MUC18
JP7090545B2 (ja) Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用
US8212010B2 (en) Sphingosine 1-phosphate antagonism
JP6286420B2 (ja) Ｂ型ボツリヌス神経毒素に対する結合／中和ヒトモノクローナル抗体
CN112368020A (zh) 抗pd-1抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法
WO2009089062A2 (en) Cadherin-11 ecl domain antagonists for treating inflammatory joint disorders
ES2382039T3 (es) Anticuerpos anti-TLR4/MD-2 neutralizantes y métodos de uso de los mismos
US10449252B2 (en) Inhibition of CD69 for treatment of inflammatory conditions
US20140249298A1 (en) ANTI-HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 (hENT1) ANTIBODIES ADN METHODS OF USE THEREOF
WO2019136516A1 (en) Methods of treating myocarditis and/or cardiomyopathy and reagents therefor
EP2398491B1 (en) Sphingosine 1-phosphate antagonism
WO2021000004A1 (en) Methods of treating myocarditis and/or cardiomyopathy and reagents therefor
US20140336365A1 (en) Cdr regions of monoclonal antibody that antagonize sphinogosine 1-phosphate and related methods
HK40005045B (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160502

R150 Certificate of patent or registration of utility model

Ref document number: 5938876

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250